

REMARKS

Claims 1-7, 9-11, 14-17 are pending in the application. Claim 8 has been cancelled Claims 16 and 17 have been added. Claims 1, 9-11 and 14 have been amended. Support for amended and newly added claims lies in the specification on page 2, lines 34-38, page 3, line 18, and page 4, lines 13-15 and 23-25. No new matter is believed added. Applicants reserve their right to file divisional or continuation applications on all cancelled or deleted subject matter. .

Claim 15 is indicated as being allowed by the Examiner and claims 2-7 are objected to. Notice of allowable subject matter is greatly appreciated.

Rejection under 35 USC §112

Claims 1, 8-10 and 14 are rejected under 35 USC §112, second paragraph as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicants regards as the invention.

The term pharmaceutically acceptable derivative is defined in the specification on page 4, lines 12 to 22 and is not believed to be indefinite. However, in order to advance prosecution on the merits this term has been amended to "pharmaceutically acceptable salt".

CONCLUSION

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below. If any additional fees or charges are required by this paper the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,



/
Dara L. Dinner
Attorney for Applicants
Registration No. 33,680

GLAXOSMITHKLINE
Corporate Intellectual Property UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5017
Facsimile (610) 270-5090